Quarterly ResultAug 11, 2026, 08:10 AM
Imunon Q2 2026 Net Loss $2.8M; IMNN-001 Trial Progress
AI Summary
Imunon, Inc. reported a net loss of $2.8 million, or $0.54 per share, for the second quarter of 2026. The company highlighted significant progress in its lead clinical program, IMNN-001, with enrollment in the pivotal Phase 3 OVATION 3 study exceeding expectations and positive preliminary data from its Phase 2 minimal residual disease study. Imunon also announced securing $10 million in financing during the quarter.
Key Highlights
- Q2 2026 net loss was $2.8 million, or $0.54 per share.
- Research and development expenses increased to $1.5 million in Q2 2026 from $1.2 million in Q2 2025.
- Cash and cash equivalents were $6.9 million as of June 30, 2026.
- Secured $10 million in financing through preferred stock and promissory notes in June 2026.
- Enrollment in the Phase 3 OVATION 3 study for IMNN-001 is exceeding planning assumptions.
- Preliminary Phase 2 MRD study data showed a 44% MRD-positive rate vs. 67% for control, and 87.5% ctDNA clearance vs. 62.5%.
- Enrollment in the Phase 3 OVATION 3 study is expected to be completed by the first half of 2029.
Price Impact
More from IMNN